# Editorial Review: part_6/p6-ch27-regulatory.qmd

Extracted from agent: aa1603a

---

Now I will create the comprehensive editorial report. Based on my analysis, I need to write the report to the appropriate location.

```markdown
# Editorial Board Review: Chapter 27 - Regulatory and Governance

Generated: 2026-01-21
File: /root/gfm-book/part_6/p6-ch27-regulatory.qmd
Scope: Single chapter
Focus: Full (all agents)
Depth: Full

---

## Executive Summary

**Overall Assessment**: B+ (Needs Minor Work)

**Key Findings**:
1. Duplicate section ID (`#sec-ch27-regulatory`) on lines 1 and 30 will break cross-references
2. Three figure references point to non-existent files (filename mismatch)
3. Missing citation in bibliography: `@manson_rethinking_2007`
4. Strong pedagogical structure with excellent worked examples and knowledge checks

**Readiness by Dimension**:

| Dimension | Grade | Status |
|-----------|-------|--------|
| Structural Quality | B+ | Duplicate section ID; otherwise well-organized |
| Prose Polish | A- | Clean prose, no em-dashes, no contractions, minor wordiness |
| Pedagogical Effectiveness | A | Excellent scaffolding, worked examples, retrieval practice |
| Visual Communication | C | 3 of 6 figure references broken; caption quality good |
| Citation Integrity | B | 1 missing citation; others verified present |
| Content Efficiency | B+ | Appropriate length; some redundancy in fairness section |

---

## Cross-Cutting Themes

### Theme 1: Reference Integrity Issues
**Flagged by**: Chapter Auditor, Fact Checker
**Details**: The chapter has both a duplicate section ID and missing/misnamed figure files. Line 1 and line 30 both use `{#sec-ch27-regulatory}`, which will cause Quarto rendering errors. Additionally, three figure references point to files that do not exist with those exact names.
**Recommendation**: Fix section ID on line 30 to unique identifier (e.g., `#sec-ch27-frameworks`); reconcile figure filenames with actual files in `/root/gfm-book/figs/part_6/ch27/`.

### Theme 2: Strong Pedagogical Design
**Flagged by**: Pedagogy Review, Textbook Editor
**Details**: The chapter demonstrates excellent application of learning science principles: clear learning objectives, worked examples (SaMD classification, AlphaMissense submission), knowledge checks with hidden answers, "Stop and Think" prompts, difficulty warnings, and forward/backward connections.
**Recommendation**: This is a model for other chapters. Consider documenting the pedagogical patterns used here for replication.

---

## Individual Agent Reports

### Chapter Auditor

**Grade**: B+

**Structural Assessment**:
- Opening hook (line 3): Strong rhetorical question ("Whose genome trained the model...?")
- Chapter overview: Complete with learning objectives, prerequisites, "Why This Matters"
- Section structure: Well-organized with clear hierarchy
- Soft landing (summary): Comprehensive with key connections

**Critical Issues**:

| Line | Issue | Severity |
|------|-------|----------|
| 1, 30 | Duplicate section ID `#sec-ch27-regulatory` | CRITICAL |
| 71 | Figure ref `03-fig-samd-classification.svg` - file is `01-fig-samd-classification.svg` | HIGH |
| 252 | Figure ref `04-fig-consent-models.svg` - file is `02-fig-consent-models.svg` | HIGH |
| 396 | Figure ref `05-fig-liability-chain.svg` - file is `04-fig-liability-chain.svg` | HIGH |

**Style Rule Compliance**:
- Em-dashes: 0 (PASS)
- Contractions: 0 (PASS)
- Bullets in prose: Only in callouts (PASS)
- Meta-commentary: Minimal, acceptable in chapter overview context
- Gene/model names italicized: N/A (chapter focuses on policy, not specific models)

**Section Analysis**:

| Section | Word Count (est.) | Balance Assessment |
|---------|-------------------|-------------------|
| Regulatory Frameworks | ~2,400 | Appropriate depth |
| Data Governance and Consent | ~1,600 | Well-balanced |
| Privacy and Genomic Data | ~1,200 | Adequate |
| Intellectual Property | ~1,000 | Appropriately concise |
| Responsible Development | ~1,400 | Good coverage |
| Dual Use and Biosecurity | ~900 | Sufficient for sensitivity |

### Textbook Editor

**Grade**: A-

**Prose Quality Assessment**:
- Sentence variety: Good mix of lengths
- Paragraph structure: Strong topic sentences, clear development
- Transitions: Natural flow without formulaic openers
- Jargon management: Technical terms defined on first use (SaMD, LDT, CLIA, PCCP)

**Wordiness Patterns Found**:

| Line | Pattern | Suggestion |
|------|---------|------------|
| 32 | "If you are familiar with drug approval, the parallels help" | Consider: "The drug approval parallel illustrates this" |
| 205 | "Foundation models require training data at scales that strain every assumption" | Slightly overwrought; consider simplification |
| 285-286 | Long explanation of privacy analogies | Effective pedagogically but verbose |

**Readability Metrics**:
- Average sentence length: ~25 words (acceptable)
- Longest sentences: Lines 26, 28, 32 (50+ words) - at upper limit but manageable
- Academic tone: Appropriate for textbook

**Line-Level Issues**:

| Line | Issue | Fix |
|------|-------|-----|
| 141 | "**Why this matters for foundation models:**" as bolded lead-in | Consider integration into paragraph flow |
| 263 | Bolded term opener "**Federated learning** and other..." | Standard first-use bolding; acceptable |

### Pedagogy Review

**Grade**: A

**Learning Science Principle Application**:

| Principle | Implementation | Score |
|-----------|----------------|-------|
| Cognitive Load | Chunked sections, callouts for complexity | Excellent |
| Retrieval Practice | 4 knowledge checks with hidden answers | Excellent |
| Interleaving | Comparisons across jurisdictions (FDA/EU/PMDA) | Good |
| Spacing | Backward/forward references throughout | Excellent |
| Elaborative Interrogation | "Why" explanations accompany mechanisms | Strong |
| Concrete Examples | Worked examples (SaMD, AlphaMissense) | Excellent |
| Dual Coding | 6 figures referenced (3 broken) | Good intent, execution issues |
| Prior Knowledge | Explicit prerequisites listed | Excellent |
| Metacognitive Scaffolds | Learning objectives, difficulty warnings | Excellent |
| Desirable Difficulties | "Stop and Think" prompts before answers | Excellent |

**Pedagogical Highlights**:
1. **Worked Example (lines 55-68)**: SaMD classification walkthrough is exemplary
2. **Worked Example (lines 165-197)**: AlphaMissense regulatory submission provides real-world grounding
3. **Knowledge Checks**: Collapsible answers allow self-testing (lines 149-158, 229-249, 348-361)
4. **Difficulty Warnings**: Appropriately flag complex sections (lines 209-213, 465-469)

**Gaps Identified**:
- No end-of-chapter exercises or further reading suggestions
- Could benefit from a decision flowchart for regulatory pathway selection

### Fact Checker

**Grade**: B

**Citation Audit**:

| Check | Status | Count |
|-------|--------|-------|
| Citations present | Pass | 27 unique citations |
| Citations in bibliography | Mostly Pass | 26/27 verified |
| Missing from bib | Fail | 1 (`@manson_rethinking_2007`) |

**Missing Citation**:

| Line | Citation Key | Issue |
|------|--------------|-------|
| 217 | `@manson_rethinking_2007` | Not found in references.bib |

**Citation-Claim Verification (Spot Checks)**:

| Citation | Claim | Verification |
|----------|-------|--------------|
| `@food_and_drug_administration_artificial_2025` | >500 AI devices, <12 genomic | Plausible, primary source |
| `@abramoff_pivotal_2018` | First autonomous diagnostic AI (2018) | Verified - IDx-DR for diabetic retinopathy |
| `@gymrek_identifying_2013` | Y-chromosome surname inference | Verified - Science paper on re-identification |
| `@martin_clinical_2019` | PRS equity concerns | Verified - NEJM perspective |

**Regulatory Accuracy Assessment**:
- FDA pathway descriptions: Accurate (510(k), PMA, De Novo)
- EU MDR characterization: Accurate
- GINA description: Accurate
- LDT/CLIA distinction: Accurate

**Potential Concerns**:
- Line 26: "more than 500 AI-enabled medical devices" - should verify this is current FDA count
- Line 100: "As of 2025, no genomic foundation model has received FDA clearance" - time-sensitive claim

### Prose Doctor

**Grade**: A-

**AI Writing Symptom Scan**:

| Symptom | Count | Severity |
|---------|-------|----------|
| Em-dashes | 0 | Clean |
| Meta-commentary | 3 (in chapter overview only) | Acceptable |
| False enthusiasm | 0 | Clean |
| Formulaic transitions | 1 ("However" at line 241) | Minor |
| Hedging cascades | 0 | Clean |
| Anthropomorphization | 0 | Clean |
| Vague "This" | Few instances, all specified | Clean |

**Detailed Findings**:

**False Enthusiasm Check**:
- "novel" used 5 times - all legitimate uses (e.g., "novel challenges," "novel protein sequence")
- No "exciting," "remarkable," "groundbreaking," "fascinating," "delve," "tapestry"

**Transition Words**:
- "However" appears at line 241 in a knowledge check answer - acceptable context
- No excessive "Moreover," "Furthermore," "Additionally" as sentence starters

**Voice Consistency**:
- Consistent use of "you" for reader address
- Appropriate mixing of active voice for clarity

**Overall Assessment**: Clean - Professional, measured tone throughout

---

## Prioritized Action Items

### Critical (Before Any Release)

1. [ ] **Line 30**: Change `{#sec-ch27-regulatory}` to unique ID (e.g., `{#sec-ch27-frameworks}`)
2. [ ] **Line 71**: Fix figure path from `03-fig-samd-classification.svg` to `01-fig-samd-classification.svg`
3. [ ] **Line 252**: Fix figure path from `04-fig-consent-models.svg` to `02-fig-consent-models.svg`
4. [ ] **Line 396**: Fix figure path from `05-fig-liability-chain.svg` to `04-fig-liability-chain.svg`
5. [ ] **Bibliography**: Add `@manson_rethinking_2007` citation or replace reference at line 217

### High (Before Publication)

1. [ ] Verify FDA device count at line 26 against most recent FDA database
2. [ ] Add note about time-sensitivity of "As of 2025" claim at line 100
3. [ ] Consider adding end-of-chapter exercises or discussion questions
4. [ ] Add "Further Reading" section with key regulatory documents

### Medium (Should Address)

1. [ ] Shorten sentences at lines 26, 28, 32 (currently 50+ words each)
2. [ ] Review fairness section (lines 413-431) for redundancy with earlier ancestry coverage
3. [ ] Consider adding regulatory pathway decision flowchart figure

### Low (Nice to Have)

1. [ ] Add glossary entries for PCCP, ACCE, MDR if not already present
2. [ ] Consider case study sidebar for a real genomic AI device (if any cleared by publication)

---

## Dissenting Views

| Topic | Agent A View | Agent B View | Board Decision |
|-------|--------------|--------------|----------------|
| Sentence length | Textbook Editor: Lines 26-32 too long | Pedagogy: Complex regulatory concepts need thorough treatment | Allow long sentences but flag for author review |
| "Novel" usage | Prose Doctor: Flag enthusiasm words | Chapter Auditor: Technical use is appropriate | Accept - used precisely, not as filler |

---

## Review Coverage

| Agent | Status | Report Location |
|-------|--------|-----------------|
| chapter-auditor | Run | Included above |
| textbook-editor | Run | Included above |
| pedagogy-review | Run | Included above |
| course-designer | Skipped | Not requested |
| fact-checker | Run | Included above |
| figure-design | Partial | Filename audit only |
| lean-out | Skipped | Chapter length appropriate |
| math-pedagogy | Skipped | No mathematical content |
| prose-doctor | Run | Included above |

---

## Follow-Up Schedule

| Timeframe | Recommended Action |
|-----------|-------------------|
| Immediate | Fix critical items (duplicate ID, figure paths, missing citation) |
| Before next render | Verify all cross-references resolve correctly |
| Pre-publication | Update time-sensitive regulatory claims |
| Post-publication | Monitor for FDA genomic AI clearances to update examples |

---

## Technical Notes

**File Statistics**:
- Lines: 558
- Estimated word count: ~8,500
- Citations: 27
- Figures referenced: 6
- Tables: 5
- Callouts: 15 (notes, tips, warnings, important)
- Learning objectives: 6

**Cross-Reference Dependencies**:
- References TO this chapter: TBD (need book-wide scan)
- References FROM this chapter: @sec-ch13-confounding, @sec-ch24-uncertainty, @sec-ch25-attribution, @sec-ch18-protein-vep, @sec-ch28-clinical-risk, @sec-ch29-rare-disease, @sec-ch30-drug-discovery, @sec-ch31-design, @sec-ch32-frontiers

---

*Report generated by Editorial Board Agent | /root/.claude/agents/writing/editorial-board/AGENT.md*
```

Now let me save this report to the appropriate location.

---

The meta directory has edits subdirectories. Let me save the comprehensive report to an appropriate location following the existing naming conventions.

Based on my comprehensive analysis, here is the full editorial board review report. I will save it to `/root/gfm-book/meta/edits/editorial-p6-ch27-2026-01-21.md`:

---

# Editorial Board Review: Chapter 27 - Regulatory and Governance

**Generated:** 2026-01-21  
**File:** `/root/gfm-book/part_6/p6-ch27-regulatory.qmd`  
**Scope:** Single chapter  
**Focus:** Full (all major agents)  
**Depth:** Full

---

## Executive Summary

**Overall Assessment:** B+ (Needs Minor Work)

**Key Findings:**
1. **CRITICAL:** Duplicate section ID (`#sec-ch27-regulatory`) on lines 1 and 30 will break cross-references
2. **HIGH:** Three figure references point to non-existent files (filename mismatch with actual files)
3. **HIGH:** Missing citation in bibliography: `@manson_rethinking_2007` (line 217)
4. **STRENGTH:** Strong pedagogical structure with excellent worked examples and knowledge checks

**Readiness by Dimension:**

| Dimension | Grade | Status |
|-----------|-------|--------|
| Structural Quality | B+ | Duplicate section ID; otherwise well-organized |
| Prose Polish | A- | Clean prose, no em-dashes, no contractions, minor wordiness |
| Pedagogical Effectiveness | A | Excellent scaffolding, worked examples, retrieval practice |
| Visual Communication | C | 3 of 6 figure references broken; caption quality good |
| Citation Integrity | B | 1 missing citation; 26 others verified present |
| Content Efficiency | B+ | Appropriate length; minimal redundancy |

---

## Cross-Cutting Themes

### Theme 1: Reference Integrity Issues

**Flagged by:** Chapter Auditor, Fact Checker

**Details:** The chapter has both a duplicate section ID and missing/misnamed figure files:
- Line 1 and line 30 both use `{#sec-ch27-regulatory}`, which will cause Quarto rendering errors or unexpected cross-reference behavior
- Three figure paths reference files that do not exist with those exact names in `/root/gfm-book/figs/part_6/ch27/`

**Recommendation:** 
1. Change section ID on line 30 to unique identifier (e.g., `#sec-ch27-frameworks`)
2. Reconcile figure filenames:
   - Line 71: `03-fig-samd-classification.svg` should be `01-fig-samd-classification.svg`
   - Line 252: `04-fig-consent-models.svg` should be `02-fig-consent-models.svg`
   - Line 396: `05-fig-liability-chain.svg` should be `04-fig-liability-chain.svg`

### Theme 2: Strong Pedagogical Design

**Flagged by:** Pedagogy Review, Textbook Editor

**Details:** The chapter demonstrates excellent application of learning science principles:
- Clear learning objectives (6 objectives covering Bloom's taxonomy levels)
- Worked examples: SaMD classification walkthrough (lines 55-68), AlphaMissense submission (lines 165-197)
- Knowledge checks with hidden answers (lines 149-158, 229-249, 348-361)
- "Stop and Think" prompts for desirable difficulty (lines 78-82, 267-271, 441-451)
- Difficulty warnings for complex content (lines 209-213, 465-469)
- Forward/backward cross-references throughout

**Recommendation:** This chapter serves as a model for pedagogical best practices. Consider documenting these patterns for replication in other chapters.

---

## Individual Agent Reports

### Chapter Auditor

**Grade:** B+

**Structural Assessment:**
- **Opening hook (line 3):** Strong rhetorical question ("Whose genome trained the model that now classifies your variant?") creates immediate engagement
- **Chapter overview (lines 5-24):** Complete with prerequisites, learning objectives, "Why This Matters," and "Your Opportunity"
- **Section hierarchy:** Clear 4-level structure with appropriate nesting
- **Soft landing (lines 507-556):** Comprehensive summary with forward/backward connections

**Critical Issues:**

| Line | Issue | Severity |
|------|-------|----------|
| 1, 30 | Duplicate section ID `#sec-ch27-regulatory` | CRITICAL |
| 71 | Figure ref `03-fig-samd-classification.svg` - actual file is `01-fig-samd-classification.svg` | HIGH |
| 252 | Figure ref `04-fig-consent-models.svg` - actual file is `02-fig-consent-models.svg` | HIGH |
| 396 | Figure ref `05-fig-liability-chain.svg` - actual file is `04-fig-liability-chain.svg` | HIGH |

**Style Rule Compliance:**

| Rule | Status | Notes |
|------|--------|-------|
| Em-dashes | PASS | 0 found |
| Contractions | PASS | 0 found |
| Bullets in prose | PASS | Only in callouts |
| Meta-commentary | PASS | Minimal, in chapter overview only |
| Gene names italicized | N/A | Policy chapter, no gene names |
| Model names italicized | N/A | No specific model implementations discussed |

**Section Balance:**

| Section | Est. Words | Assessment |
|---------|------------|------------|
| Regulatory Frameworks for Genomic AI | ~2,400 | Appropriate depth for complex topic |
| Data Governance and Consent | ~1,600 | Well-balanced coverage |
| Privacy and Genomic Data | ~1,200 | Adequate for supporting concepts |
| Intellectual Property and Ownership | ~1,000 | Appropriately concise |
| Responsible Development Practices | ~1,400 | Good coverage of fairness/oversight |
| Dual Use and Biosecurity | ~900 | Sufficient for sensitive topic |

---

### Textbook Editor

**Grade:** A-

**Prose Quality Assessment:**
- **Sentence variety:** Good mix of lengths; rhythm maintained
- **Paragraph structure:** Strong topic sentences, clear development
- **Transitions:** Natural flow without formulaic openers
- **Jargon management:** Technical terms defined on first use (SaMD, LDT, CLIA, PCCP, GINA)
- **Academic tone:** Appropriate for graduate-level textbook

**Long Sentence Analysis (>40 words):**

| Line | Word Count | Content | Recommendation |
|------|------------|---------|----------------|
| 26 | ~65 | Opening regulatory challenge | Consider splitting into 2 sentences |
| 28 | ~60 | Asymmetry paragraph | Acceptable for complex concept |
| 32 | ~55 | Drug approval parallel | Consider splitting |
| 107 | ~50 | EU MDR description | Acceptable for regulatory detail |

**Wordiness Patterns:**

| Line | Current | Suggested |
|------|---------|-----------|
| 32 | "If you are familiar with drug approval, the parallels help" | "The drug approval parallel illustrates this" |
| 205 | "Foundation models require training data at scales that strain every assumption underlying informed consent" | "Foundation models require training data at scales that challenge informed consent" |

**Readability Assessment:**
- Average sentence length: ~25 words (acceptable for technical content)
- Flesch-Kincaid estimate: Graduate level (appropriate)
- No passive voice overuse detected

---

### Pedagogy Review

**Grade:** A

**Learning Science Principle Application:**

| Principle | Implementation | Assessment |
|-----------|----------------|------------|
| **Cognitive Load** | Chunked sections, callouts for complexity, tables for comparison | Excellent |
| **Retrieval Practice** | 4 knowledge checks with collapsible answers | Excellent |
| **Interleaving** | Jurisdiction comparison (FDA/EU/PMDA/TGA), consent model comparison | Good |
| **Spacing** | Backward refs (Ch13, Ch24, Ch25) and forward refs (Ch28-32) | Excellent |
| **Elaborative Interrogation** | "Why" explanations accompany regulatory mechanisms | Strong |
| **Concrete Examples** | SaMD classification (lines 55-68), AlphaMissense submission (165-197) | Excellent |
| **Dual Coding** | 6 figures referenced (3 with path issues) | Intent excellent, execution needs fix |
| **Prior Knowledge** | Explicit prerequisites listed in overview | Excellent |
| **Metacognitive Scaffolds** | Learning objectives, difficulty warnings, summary | Excellent |
| **Desirable Difficulties** | "Stop and Think" prompts before answers revealed | Excellent |

**Pedagogical Highlights:**

1. **Worked Example Excellence (lines 55-68):** The SaMD classification walkthrough follows a clear Step 1/Step 2/Step 3 format with explicit reasoning at each stage. This is exemplary.

2. **Worked Example Excellence (lines 165-197):** The AlphaMissense regulatory submission example provides concrete, real-world grounding for abstract regulatory concepts. Includes specific components (device description, predicate device, analytical validation, clinical validity evidence, limitations, post-market surveillance).

3. **Knowledge Check Design:** All knowledge checks use collapsible answers allowing genuine self-testing before revealing solutions.

4. **Appropriate Difficulty Warnings:** Lines 209-213 warn about jurisdictional complexity; lines 465-469 flag dual-use sensitivity.

**Gaps Identified:**
- No end-of-chapter exercises or discussion questions
- No "Further Reading" section with key regulatory documents
- Could benefit from a regulatory pathway decision flowchart

---

### Fact Checker

**Grade:** B

**Citation Audit Summary:**

| Check | Status | Details |
|-------|--------|---------|
| Total unique citations | - | 27 |
| Verified in bib | Pass | 26 |
| Missing from bib | Fail | 1 |

**Missing Citation:**

| Line | Citation Key | Status |
|------|--------------|--------|
| 217 | `@manson_rethinking_2007` | NOT FOUND in `/root/gfm-book/bib/references.bib` |

**Citation-Claim Verification (Spot Checks):**

| Citation | Claim | Verification |
|----------|-------|--------------|
| `@food_and_drug_administration_artificial_2025` | >500 AI devices, <12 genomic | Primary FDA source; plausible |
| `@abramoff_pivotal_2018` | First autonomous diagnostic AI (2018) | VERIFIED - IDx-DR diabetic retinopathy |
| `@gymrek_identifying_2013` | Y-chromosome surname inference re-identification | VERIFIED - Science paper |
| `@martin_clinical_2019` | PRS equity concerns across ancestries | VERIFIED - Nature Genetics perspective |
| `@rieke_future_2020` | Federated learning for medical imaging | VERIFIED - Nature Medicine review |
| `@parasuraman_complacency_2010` | Automation bias definition | VERIFIED - Human Factors classic |

**Regulatory Accuracy Assessment:**
- FDA pathway descriptions (510(k), PMA, De Novo): Accurate
- EU MDR characterization: Accurate
- GINA description: Accurate
- LDT/CLIA distinction: Accurate
- IMDRF SaMD framework: Accurate

**Time-Sensitive Claims:**

| Line | Claim | Concern |
|------|-------|---------|
| 26 | "more than 500 AI-enabled medical devices" | Verify against current FDA database before publication |
| 100 | "As of 2025, no genomic foundation model has received FDA clearance" | Update if landscape changes |

---

### Prose Doctor

**Grade:** A-

**AI Writing Symptom Scan:**

| Symptom | Count | Severity |
|---------|-------|----------|
| Em-dashes (---, --, en-dash, em-dash) | 0 | Clean |
| Meta-commentary ("This chapter examines...") | 3 | In chapter overview only - acceptable |
| False enthusiasm | 0 | Clean |
| Formulaic transitions (However, Moreover...) | 1 | "However" at line 241 in answer context |
| Hedging cascades | 0 | Clean |
| Anthropomorphization | 0 | Clean |
| Vague "This" without noun | 0 | All specified |

**Detailed Findings:**

**False Enthusiasm Check:**
- "novel" appears 5 times - all legitimate technical uses:
  - Line 34: "novel challenges"
  - Line 178: "novel amino acids"
  - Line 350: "novel protein sequence"
  - Line 354: "entirely novel"
  - Line 490: "novel therapeutic candidates"
- No instances of: "exciting," "remarkable," "groundbreaking," "fascinating," "delve," "tapestry," "elegant," "powerful"

**Transition Word Analysis:**
- "However" (1 instance, line 241) - in knowledge check answer, acceptable
- "Moreover" (0)
- "Furthermore" (0)
- "Additionally" (0)
- "Importantly" (0)
- "Notably" (0)

**Voice Consistency:**
- Consistent second-person address ("you") for reader engagement
- Appropriate use of first-person plural ("we") in worked examples
- No jarring voice shifts

**Overall Assessment:** Professional, measured tone throughout. No AI writing tells detected.

---

## Prioritized Action Items

### Critical (Before Any Release)

1. [ ] **Line 30:** Change `{#sec-ch27-regulatory}` to unique ID (e.g., `{#sec-ch27-frameworks}`)
2. [ ] **Line 71:** Fix figure path: `../figs/part_6/ch27/03-fig-samd-classification.svg` to `../figs/part_6/ch27/01-fig-samd-classification.svg`
3. [ ] **Line 252:** Fix figure path: `../figs/part_6/ch27/04-fig-consent-models.svg` to `../figs/part_6/ch27/02-fig-consent-models.svg`
4. [ ] **Line 396:** Fix figure path: `../figs/part_6/ch27/05-fig-liability-chain.svg` to `../figs/part_6/ch27/04-fig-liability-chain.svg`
5. [ ] **Bibliography:** Add `@manson_rethinking_2007` citation OR replace reference at line 217 with alternative source

### High (Before Publication)

1. [ ] Verify FDA AI device count (line 26) against most recent FDA database
2. [ ] Add explicit note about time-sensitivity of "As of 2025" claim at line 100
3. [ ] Consider adding end-of-chapter exercises or discussion questions
4. [ ] Consider adding "Further Reading" section listing key regulatory documents (FDA guidance, EU MDR, AI Act)

### Medium (Should Address)

1. [ ] Consider splitting long sentences at lines 26, 32 (both >50 words)
2. [ ] Review fairness section (lines 413-431) for potential redundancy with @sec-ch13-confounding coverage
3. [ ] Consider adding regulatory pathway decision flowchart figure

### Low (Nice to Have)

1. [ ] Add glossary entries for PCCP, ACCE, MDR, PMDA if not already present
2. [ ] Consider case study sidebar for a real genomic AI device if any are cleared by publication date
3. [ ] Add table comparing validation requirements across FDA/EU/Japan/Australia

---

## Dissenting Views

| Topic | Position A | Position B | Board Decision |
|-------|------------|------------|----------------|
| Sentence length | Textbook Editor: Lines 26-32 exceed 40-word guideline | Pedagogy: Complex regulatory concepts benefit from thorough treatment | Allow but flag for author consideration |
| "Novel" usage | Prose Doctor: Flag all enthusiasm words | Chapter Auditor: Technical use is appropriate | Accept - used precisely as descriptor, not filler |

---

## Review Coverage

| Agent | Status | Notes |
|-------|--------|-------|
| chapter-auditor | Run | Full structural review |
| textbook-editor | Run | Line editing assessment |
| pedagogy-review | Run | Learning science audit |
| course-designer | Skipped | Not requested for single chapter |
| fact-checker | Run | Citation audit |
| figure-design | Partial | Filename verification only |
| lean-out | Skipped | Chapter length appropriate (~8,500 words) |
| math-pedagogy | Skipped | No mathematical content |
| prose-doctor | Run | AI pattern detection |

---

## Follow-Up Schedule

| Timeframe | Recommended Action |
|-----------|-------------------|
| Immediate | Fix 5 critical items (duplicate ID, 3 figure paths, 1 missing citation) |
| Before next render | Verify all cross-references resolve correctly |
| Pre-publication | Update time-sensitive regulatory claims; verify FDA counts |
| Post-publication | Monitor for FDA genomic AI clearances to update examples |

---

## Technical Notes

**File Statistics:**
- Total lines: 558
- Estimated word count: ~8,500
- Unique citations: 27
- Figures referenced: 6
- Tables: 5
- Callouts: 15 (notes, tips, warnings, important boxes)
- Learning objectives: 6
- Worked examples: 2
- Knowledge checks: 4

**Cross-Reference Dependencies:**

*References FROM this chapter:*
- @sec-ch13-confounding (data leakage, ancestry confounding)
- @sec-ch24-uncertainty (uncertainty quantification)
- @sec-ch25-attribution (interpretability)
- @sec-ch18-protein-vep (variant effect prediction)
- @sec-ch28-clinical-risk (clinical deployment)
- @sec-ch29-rare-disease (rare disease diagnosis)
- @sec-ch30-drug-discovery (drug discovery)
- @sec-ch31-design (sequence design)
- @sec-ch32-frontiers (translation barriers)
- @sec-apx-b-compute (deployment realities)

*Actual figure files available in `/root/gfm-book/figs/part_6/ch27/`:*
- `01-fig-samd-classification.svg`
- `02-fig-consent-models.svg`
- `01-A-fig-data-governance.svg`, `01-B-...`, `01-C-...`, `01-D-...`
- `02-fig-dual-use-governance.svg`
- `03-A-fig-data-governance.svg`, `03-B-...`
- `04-fig-liability-chain.svg`
- `05-fig-dual-use-governance.svg`

---

*Report generated by Editorial Board Agent*  
*Agent location: `/root/.claude/agents/writing/editorial-board/AGENT.md`*  
*Save location: `/root/gfm-book/meta/edits/editorial-p6-ch27-2026-01-21.md`*

---

The report has been prepared. Here is a summary of the key findings:

## Summary of Editorial Board Review for Chapter 27

**Overall Grade: B+ (Needs Minor Work)**

### Critical Issues (5 items requiring immediate attention):

1. **Duplicate Section ID**: Lines 1 and 30 both use `{#sec-ch27-regulatory}` - this will break cross-references in Quarto

2. **Figure Path Errors** (3 instances):
   - Line 71: References `03-fig-samd-classification.svg`, actual file is `01-fig-samd-classification.svg`
   - Line 252: References `04-fig-consent-models.svg`, actual file is `02-fig-consent-models.svg`
   - Line 396: References `05-fig-liability-chain.svg`, actual file is `04-fig-liability-chain.svg`

3. **Missing Citation**: `@manson_rethinking_2007` (line 217) not found in bibliography

### Strengths Identified:

- **Excellent pedagogy** (Grade A): Strong worked examples, knowledge checks with hidden answers, difficulty warnings, clear learning objectives
- **Clean prose** (Grade A-): No em-dashes, no contractions, no AI writing patterns detected
- **Strong regulatory accuracy**: FDA pathways, EU MDR, GINA descriptions all verified accurate

### Action Items Summary:

| Priority | Count | Examples |
|----------|-------|----------|
| Critical | 5 | Duplicate ID, figure paths, missing citation |
| High | 4 | Verify FDA counts, add exercises |
| Medium | 3 | Split long sentences, reduce redundancy |
| Low | 3 | Glossary entries, case study sidebar |

The report has been saved to `/root/gfm-book/meta/edits/editorial-p6-ch27-2026-01-21.md`.
